AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents

Grant

Awarded By

Total Award Amount

  • 1162.00

    • Direct Costs

  • 924.00

    • Sponsor Award Id

    • Contributor

  • Ana Xavier   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator